Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. Naumann RW, et al. Among authors: symanowski jt. J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127448 Clinical Trial.
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Herzog TJ, Kutarska E, Bidzińsk M, Symanowski J, Nguyen B, Rangwala RA, Naumann RW. Herzog TJ, et al. Int J Gynecol Cancer. 2016 Nov;26(9):1580-1585. doi: 10.1097/IGC.0000000000000806. Int J Gynecol Cancer. 2016. PMID: 27654255 Clinical Trial.
Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
Morris RT, Joyrich RN, Naumann RW, Shah NP, Maurer AH, Strauss HW, Uszler JM, Symanowski JT, Ellis PR, Harb WA. Morris RT, et al. Among authors: symanowski jt. Ann Oncol. 2014 Apr;25(4):852-858. doi: 10.1093/annonc/mdu024. Ann Oncol. 2014. PMID: 24667717 Free article. Clinical Trial.
Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, Foureau DM, Maxwell DM, Baldrige EA, Begic X, Symanowski JT, Steuerwald NM, Anderson CJ, Patt JC, Kneisl JS, Kim ES. Livingston MB, et al. Among authors: symanowski jt. Clin Cancer Res. 2021 Dec 1;27(23):6424-6431. doi: 10.1158/1078-0432.CCR-21-2001. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475102 Clinical Trial.
Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients.
Farhangfar CJ, Scarola GT, Morris VA, Farhangfar F, Dumas K, Symanowski J, Hwang JJ, Mileham KF, Carrizosa DR, Naumann RW, Livasy C, Kim ES, Raghavan D. Farhangfar CJ, et al. JCO Clin Cancer Inform. 2022 Jul;6:e2200011. doi: 10.1200/CCI.22.00011. JCO Clin Cancer Inform. 2022. PMID: 35839431 Free article.
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
Burri SH, Prabhu RS, Sumrall AL, Brick W, Blaker BD, Heideman BE Jr, Boltes P, Kelly R, Symanowski JT, Wiggins WF, Ashby L, Norton HJ, Judy K, Asher AL. Burri SH, et al. Among authors: symanowski jt. J Neurooncol. 2015 Jun;123(2):259-66. doi: 10.1007/s11060-015-1793-2. Epub 2015 May 7. J Neurooncol. 2015. PMID: 25947286 Clinical Trial.
HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK. Miller KR, et al. Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022. Gynecol Oncol. 2018. PMID: 29402501
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Mittendorf EA, et al. Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30. Ann Oncol. 2016. PMID: 27029708 Free PMC article. Clinical Trial.
84 results